Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2008 Dec 01;746:1496-511. doi: 10.1124/mol.108.048892.
Show Gene links
Show Anatomy links
Multiple pharmacophores for the selective activation of nicotinic alpha7-type acetylcholine receptors.
Horenstein NA, Leonik FM, Papke RL.
???displayArticle.abstract???
The activation of heteromeric and homomeric nicotinic acetylcholine receptors was studied in Xenopus laevis oocytes to identify key structures of putative agonist molecules associated with the selective activation of homomeric alpha7 receptors. We observed that selectivity between alpha7 and alpha4beta2 was more readily obtained than selectivity between alpha7 and alpha3beta4. Based on structural comparisons of previously characterized selective and nonselective agonists, we hypothesize at least three chemical motifs exist that, when present in molecules containing an appropriate cationic center, could be associated with the selective activation of alpha7 receptors. We identify the three distinct structural motifs based on prototypical drugs as the choline motif, the tropane motif, and the benzylidene motif. The choline motif involves the location of an oxygen-containing polar group such as a hydroxyl or carbonyl separated by two carbons from the charged nitrogen. The tropane motif provides alpha7-selectivity based on the addition of multiple small hydrophobic groups positioned away from the cationic center in specific orientations. We show that this motif can convert the nonselective agonists quinuclidine and ethyltrimethyl-ammonium to the alpha7-selective analogs methyl-quinuclidine and diethyldimethyl-ammonium, respectively. We have shown previously that the benzylidene group of 3-2,4, dimethoxy-benzylidene anabaseine (GTS-21) converts anabaseine into an alpha7-selective agonist. The benzylidene motif was also applied to quinuclidine to generate another distinct family of alpha7-selective agonists. Our results provide insight for the further development of nicotinic therapeutics and will be useful to direct future experiments with protein structure-based modeling and site-directed mutagenesis.
Acker,
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.
2008, Pubmed
Acker,
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity.
2008,
Pubmed Beers,
Structure and activity of acetylcholine.
1970,
Pubmed Biton,
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile.
2007,
Pubmed
,
Xenbase Bodnar,
Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.
2005,
Pubmed Boess,
The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
2007,
Pubmed
,
Xenbase Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed Briggs,
alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues.
2008,
Pubmed Broad,
PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor.
2002,
Pubmed
,
Xenbase Buisson,
Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.
2001,
Pubmed Dani,
Overview of nicotinic receptors and their roles in the central nervous system.
2001,
Pubmed de Fiebre,
Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes.
1995,
Pubmed
,
Xenbase Efange,
2-(2-Piperidyl)- and 2-(2-pyrrolidyl)chromans as nicotine agonists: synthesis and preliminary pharmacological characterization.
2001,
Pubmed
,
Xenbase Feuerbach,
JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist.
2007,
Pubmed
,
Xenbase Flores,
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment.
1992,
Pubmed Francis,
Specific activation of the alpha 7 nicotinic acetylcholine receptor by a quaternary analog of cocaine.
2001,
Pubmed
,
Xenbase Gotti,
Brain nicotinic acetylcholine receptors: native subtypes and their relevance.
2006,
Pubmed Heinemann,
The brain nicotinic acetylcholine receptor gene family.
1990,
Pubmed Higgins,
A desensitized form of neuronal acetylcholine receptor detected by 3H-nicotine binding on bovine adrenal chromaffin cells.
1988,
Pubmed Higgins,
CLUSTAL V: multiple alignment of DNA and protein sequences.
1994,
Pubmed Horenstein,
Reversal of agonist selectivity by mutations of conserved amino acids in the binding site of nicotinic acetylcholine receptors.
2007,
Pubmed
,
Xenbase Kem,
Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration.
2004,
Pubmed
,
Xenbase Le Novère,
The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences.
2002,
Pubmed Le Novère,
Models of the extracellular domain of the nicotinic receptors and of agonist- and Ca2+-binding sites.
2002,
Pubmed Leonik,
Quinuclidines as selective agonists for alpha-7 nicotinic acetylcholine receptors.
2007,
Pubmed
,
Xenbase Lopez-Hernandez,
Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons.
2007,
Pubmed
,
Xenbase Machu,
Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine(3A) receptor.
2001,
Pubmed
,
Xenbase Macor,
The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.
2001,
Pubmed
,
Xenbase Marrero,
The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase.
2004,
Pubmed Mazurov,
Selective alpha7 nicotinic acetylcholine receptor ligands.
2006,
Pubmed Meyer,
Analysis of 3-(4-hydroxy, 2-Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha-7 nicotinic receptors.
1998,
Pubmed
,
Xenbase Meyer,
Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties.
1998,
Pubmed
,
Xenbase Meyer,
3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat alpha7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner.
1997,
Pubmed
,
Xenbase Mukhtasimova,
Initial coupling of binding to gating mediated by conserved residues in the muscle nicotinic receptor.
2005,
Pubmed Mullen,
(-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor.
2000,
Pubmed
,
Xenbase Papke,
Estimation of both the potency and efficacy of alpha7 nAChR agonists from single-concentration responses.
2006,
Pubmed
,
Xenbase Papke,
Effects at a distance in alpha 7 nAChR selective agonists: benzylidene substitutions that regulate potency and efficacy.
2004,
Pubmed
,
Xenbase Papke,
Activity of alpha7-selective agonists at nicotinic and serotonin 5HT3 receptors expressed in Xenopus oocytes.
2004,
Pubmed
,
Xenbase Papke,
The characterization of a novel rigid nicotine analog with alpha7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion.
2005,
Pubmed
,
Xenbase Papke,
Molecular dissection of tropisetron, an alpha7 nicotinic acetylcholine receptor-selective partial agonist.
2005,
Pubmed
,
Xenbase Papke,
Comparative pharmacology of rat and human alpha7 nAChR conducted with net charge analysis.
2002,
Pubmed
,
Xenbase Papke,
alpha7 receptor-selective agonists and modes of alpha7 receptor activation.
2000,
Pubmed Papke,
An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the alpha 7 subtype.
1996,
Pubmed
,
Xenbase Sheridan,
The ensemble approach to distance geometry: application to the nicotinic pharmacophore.
1986,
Pubmed Stokes,
The structural basis for GTS-21 selectivity between human and rat nicotinic alpha7 receptors.
2004,
Pubmed
,
Xenbase Tatsumi,
(+)-3-[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the alpha7 nicotinic acetylcholine receptor.
2004,
Pubmed Tatsumi,
Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand.
2005,
Pubmed Tatsumi,
(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.
2006,
Pubmed Tønder,
An improved nicotinic pharmacophore and a stereoselective CoMFA-model for nicotinic agonists acting at the central nicotinic acetylcholine receptors labelled by.
2001,
Pubmed Turner,
Nicotinic cholinergic receptors in the rat cerebellum: multiple heteromeric subtypes.
2005,
Pubmed Verbitsky,
Mixed nicotinic-muscarinic properties of the alpha9 nicotinic cholinergic receptor.
2000,
Pubmed
,
Xenbase Wishka,
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
2006,
Pubmed
